These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 25258390)

  • 41. The use of the 13C-dextromethorphan breath test for phenotyping CYP2D6 in breast cancer patients using tamoxifen: association with CYP2D6 genotype and serum endoxifen levels.
    Opdam FL; Dezentje VO; den Hartigh J; Modak AS; Vree R; Batman E; Smorenburg CH; Nortier JW; Gelderblom H; Guchelaar HJ
    Cancer Chemother Pharmacol; 2013 Mar; 71(3):593-601. PubMed ID: 23228987
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A prospective case series of women with estrogen receptor-positive breast cancer: levels of tamoxifen metabolites in controlled ovarian stimulation with high-dose tamoxifen.
    Balkenende EM; Dahhan T; Linn SC; Jager NG; Beijnen JH; Goddijn M
    Hum Reprod; 2013 Apr; 28(4):953-9. PubMed ID: 23335608
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Keratinocyte growth factor (KGF) induces tamoxifen (Tam) resistance in human breast cancer MCF-7 cells.
    Chang HL; Sugimoto Y; Liu S; Ye W; Wang LS; Huang YW; Lin YC
    Anticancer Res; 2006; 26(3A):1773-84. PubMed ID: 16827106
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Application of Mice Humanized for CYP2D6 to the Study of Tamoxifen Metabolism and Drug-Drug Interaction with Antidepressants.
    MacLeod AK; McLaughlin LA; Henderson CJ; Wolf CR
    Drug Metab Dispos; 2017 Jan; 45(1):17-22. PubMed ID: 27756789
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Tamoxifen Metabolism and Efficacy in Breast Cancer: A Prospective Multicenter Trial.
    Neven P; Jongen L; Lintermans A; Van Asten K; Blomme C; Lambrechts D; Poppe A; Wildiers H; Dieudonné AS; Brouckaert O; Decloedt J; Berteloot P; Verhoeven D; Joerger M; Vuylsteke P; Wynendaele W; Casteels M; Van Huffel S; Lybaert W; Van Ginderachter J; Paridaens R; Vergote I; Dezentjé VO; Van Calster B; Guchelaar HJ
    Clin Cancer Res; 2018 May; 24(10):2312-2318. PubMed ID: 29459457
    [No Abstract]   [Full Text] [Related]  

  • 46. Influence of the length and positioning of the antiestrogenic side chain of endoxifen and 4-hydroxytamoxifen on gene activation and growth of estrogen receptor positive cancer cells.
    Maximov PY; Fernandes DJ; McDaniel RE; Myers CB; Curpan RF; Jordan VC
    J Med Chem; 2014 Jun; 57(11):4569-83. PubMed ID: 24805199
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Exploiting Pharmacokinetic Models of Tamoxifen and Endoxifen to Identify Factors Causing Subtherapeutic Concentrations in Breast Cancer Patients.
    Klopp-Schulze L; Joerger M; Wicha SG; Ter Heine R; Csajka C; Parra-Guillen ZP; Kloft C
    Clin Pharmacokinet; 2018 Feb; 57(2):229-242. PubMed ID: 28540639
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Advances in the research of pharmacogenomics of tamoxifen].
    Xiong W; Zhao JJ; Wang L; Jiang XH; Tao XQ
    Yao Xue Xue Bao; 2016 Sep; 51(9):1356-67. PubMed ID: 29924509
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The Influences of Adherence to Tamoxifen and CYP2D6 Pharmacogenetics on Plasma Concentrations of the Active Metabolite (Z)-Endoxifen in Breast Cancer.
    Nardin JM; Schroth W; Almeida TA; Mürdter T; Picolotto S; Vendramini ECL; Hoppe R; Kogin JP; Miqueleto D; de Moraes SDR; Schwab M; Pecoits-Filho RF; Brauch H; Casali-da-Rocha JC
    Clin Transl Sci; 2020 Mar; 13(2):284-292. PubMed ID: 31573754
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Mechanisms of resistance to structurally diverse antiestrogens differ under premenopausal and postmenopausal conditions: evidence from in vitro breast cancer cell models.
    Fan P; Yue W; Wang JP; Aiyar S; Li Y; Kim TH; Santen RJ
    Endocrinology; 2009 May; 150(5):2036-45. PubMed ID: 19179445
    [TBL] [Abstract][Full Text] [Related]  

  • 51. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial.
    Regan MM; Leyland-Jones B; Bouzyk M; Pagani O; Tang W; Kammler R; Dell'orto P; Biasi MO; Thürlimann B; Lyng MB; Ditzel HJ; Neven P; Debled M; Maibach R; Price KN; Gelber RD; Coates AS; Goldhirsch A; Rae JM; Viale G;
    J Natl Cancer Inst; 2012 Mar; 104(6):441-51. PubMed ID: 22395644
    [TBL] [Abstract][Full Text] [Related]  

  • 52. TGFbeta2 and TbetaRII are valid molecular biomarkers for the antiproliferative effects of tamoxifen and tamoxifen metabolites in breast cancer cells.
    Buck MB; Coller JK; Mürdter TE; Eichelbaum M; Knabbe C
    Breast Cancer Res Treat; 2008 Jan; 107(1):15-24. PubMed ID: 18043895
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Hot flashes are not predictive for serum concentrations of tamoxifen and its metabolites.
    Jager NG; Koornstra RH; Vincent AD; van Schaik RH; Huitema AD; Korse TM; Schellens JH; Linn SC; Beijnen JH
    BMC Cancer; 2013 Dec; 13():612. PubMed ID: 24373320
    [TBL] [Abstract][Full Text] [Related]  

  • 54. CYP2D6 and tamoxifen: DNA matters in breast cancer.
    Hoskins JM; Carey LA; McLeod HL
    Nat Rev Cancer; 2009 Aug; 9(8):576-86. PubMed ID: 19629072
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Tamoxifen metabolites treatment promotes ERα+ transition to triple negative phenotype in vitro, effects of LDL in chemoresistance.
    Muñoz-Ayala A; Chimal-Vega B; Serafín-Higuera N; Galindo-Hernández O; Ramírez-Rosales G; Córdova-Guerrero I; Gómez-Lucas LF; García-González V
    Biosci Rep; 2024 Aug; 44(8):. PubMed ID: 39034849
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Population pharmacokinetic modelling to assess the impact of CYP2D6 and CYP3A metabolic phenotypes on the pharmacokinetics of tamoxifen and endoxifen.
    ter Heine R; Binkhorst L; de Graan AJ; de Bruijn P; Beijnen JH; Mathijssen RH; Huitema AD
    Br J Clin Pharmacol; 2014 Sep; 78(3):572-86. PubMed ID: 24697814
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dextromethorphan as a phenotyping test to predict endoxifen exposure in patients on tamoxifen treatment.
    de Graan AJ; Teunissen SF; de Vos FY; Loos WJ; van Schaik RH; de Jongh FE; de Vos AI; van Alphen RJ; van der Holt B; Verweij J; Seynaeve C; Beijnen JH; Mathijssen RH
    J Clin Oncol; 2011 Aug; 29(24):3240-6. PubMed ID: 21768449
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Antiestrogenic and DNA damaging effects induced by tamoxifen and toremifene metabolites.
    Liu X; Pisha E; Tonetti DA; Yao D; Li Y; Yao J; Burdette JE; Bolton JL
    Chem Res Toxicol; 2003 Jul; 16(7):832-7. PubMed ID: 12870885
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Increasing tamoxifen dose in breast cancer patients based on CYP2D6 genotypes and endoxifen levels: effect on active metabolite isomers and the antiestrogenic activity score.
    Barginear MF; Jaremko M; Peter I; Yu C; Kasai Y; Kemeny M; Raptis G; Desnick RJ
    Clin Pharmacol Ther; 2011 Oct; 90(4):605-11. PubMed ID: 21900890
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Estimation of tamoxifen metabolite concentrations in the blood of breast cancer patients through CYP2D6 genotype activity score.
    Wu AH; Lorizio W; Tchu S; Lynch K; Gerona R; Ji W; Ruan W; Ruddy KJ; Desantis SD; Burstein HJ; Ziv E
    Breast Cancer Res Treat; 2012 Jun; 133(2):677-83. PubMed ID: 22294487
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.